CompletedNot Applicable

Web-Based Exercise for Neuropathy and Quality of Life in Breast Cancer

Turkey (Türkiye)90 participantsStarted 2025-05-28

Plain-language summary

Chemotherapy is a widely used treatment method for cancer patients. However, various side effects may occur depending on the drug used, treatment duration, and dosage. One of these side effects is chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common complication that negatively affects patients' quality of life due to nerve damage. In particular, taxane-based chemotherapy drugs (e.g., docetaxel and paclitaxel), which are commonly used in the treatment of breast cancer, can lead to peripheral neuropathy. Studies indicate that the incidence of taxane-induced neuropathy ranges between 61% and 92%. While this condition primarily presents with sensory symptoms, it can also affect motor and autonomic nervous system functions in some patients. Currently, pharmacological treatments for preventing CIPN are limited. Aside from duloxetine, no medication has been proven effective. Therefore, non-pharmacological approaches, such as exercise, are considered an important alternative for alleviating neuropathy symptoms. Exercise is emerging as an effective method for preventing and managing peripheral neuropathy during cancer treatment. Research suggests that regular exercise has positive effects on the nervous system and can help reduce neuropathic symptoms, thereby improving patients' quality of life. This randomized controlled trial aims to evaluate the effects of a web-based exercise program on neuropathic symptoms and quality of life in breast cancer patients undergoing chemotherapy. The study consists of two phases: In the first phase, a web-based exercise program will be developed under the guidance of a physiotherapist to help manage neuropathic symptoms. In the second phase, the effectiveness of this program will be assessed. Data will be collected using the Patient Information Form, Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT), and the EORTC QLQ-C30 Quality of Life Questionnaire. Evaluations will be conducted before the intervention and at the end of an 8-week period in both the intervention and control groups. This study aims to demonstrate the potential effects of web-based exercise programs in alleviating neuropathic symptoms and improving quality of life in cancer patients.

Who can participate

Age range

18 Years – 75 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Able to understand and speak Turkish, * Over 18 years of age, * Receiving taxane-based chemotherapy in daytime chemotherapy units, * Reporting at least one neuropathy symptom according to CIPNAT, * Diagnosed with stage II-III breast cancer, * Receiving a planned weekly taxane-based chemotherapy infusion dose (70-99 mg/m², 100-129 mg/m², 130-159 mg/m², 160 mg/m² and above) and completing 8 treatment cycles, * Having internet access, * No history of deep vein thrombosis, * Not using anticoagulant medication, * Willing to participate in the study. Exclusion Criteria: * Younger than 18 years or older than 75 years, * Having central nervous system disorders affecting movement, balance, sensation, or coordination, * Presence of any skin infection, scar tissue, inflammation, or incision on the hands or ankles, * Diagnosed with a proven cardiac condition or using medication for cardiac issues, * Pregnant women or those in the postpartum period, * History of polyneuropathy before chemotherapy, * Cognitive impairment, * Presence of metal implants in the exposure area, * History of any other malignancy, * Undergoing mastectomy. Withdrawal Criteria * Patients meeting the following conditions will be withdrawn from the study: * Patients whose taxane treatment protocol is changed, * Patients who wish to withdraw from the study, * Patients with a pulse rate above 100 bpm, * Patients receiving fewer than four weekly chemotherapy applications, * Women without intern…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT)

Timeframe: At baseline (first visit) and at 8 weeks

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Timeframe: At baseline (first visit) and at 8 weeks

Trial details

NCT IDNCT06879678

SponsorBilecik Seyh Edebali Universitesi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-16

View on ClinicalTrials.gov More Chemotherapy-Induced Peripheral Neuropathy (CIPN) trials